[1-11C]Acetate uptake is not increased in renal cell carcinoma

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • J. Kotzerke - , Department of Nuclear Medicine (Author)
  • C. Linné - , Department of Urology (Author)
  • M. Meinhardt - , Institute of Pathology (Author)
  • J. Steinbach - , Helmholtz-Zentrum Dresden-Rossendorf (HZDR) (Author)
  • M. Wirth - , Department of Urology (Author)
  • G. Baretton - , Institute of Pathology (Author)
  • N. Abolmaali - , OncoRay - National Centre for Radiation Research in Oncology (Author)
  • B. Beuthien-Baumann - , Department of Nuclear Medicine (Author)

Abstract

Purpose: The purpose of this study was to investigate the potential of [1-11C]acetate (AC) as a metabolic tracer for renal cell cancer in human subjects. Methods: Twenty-one patients with suspected kidney tumours were investigated with AC and dynamic PET. AC uptake was scored on a five-step scale. Tumour localisation was known from CT/MRI. Histology was available in 18/21 patients. The results in these 18 patients are reported. Results: AC uptake by the tumour was less than (n = 11), equal to (n = 5) or higher than (n = 2) uptake in the surrounding renal parenchyma. Histological tumour types showed a typical distribution, with a predominance of clear cell carcinomas (n = 14) and only a small number of papillary cell carcinomas (n = 2) and oncocytomas (n = 2). Only the benign oncocytomas were highly positive with AC. Conclusion: In most kidney tumours the AC accumulation was not higher than in normal kidney parenchyma. Therefore, AC PET cannot be recommend for the characterisation of a renal mass.

Details

Original languageEnglish
Pages (from-to)884-888
Number of pages5
JournalEuropean journal of nuclear medicine and molecular imaging
Volume34
Issue number6
Publication statusPublished - Jun 2007
Peer-reviewedYes

External IDs

PubMed 17262213

Keywords

Sustainable Development Goals

Keywords

  • [1-C]acetate, Kidney tumour, Positron emission tomography